2-amino-N-(3,5-bis(trifluoromethyl)benzyl)acetamide | 279682-93-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-N-(3,5-bis(trifluoromethyl)benzyl)acetamide
• 英文别名: N-[3,5-Bis(trifluoromethyl)benzyl]-2-aminoacetamide；2-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]acetamide
• CAS: 279682-93-8
• 化学式: C₁₁H₁₀F₆N₂O
• 分子量: 300.204
• InChiKey: OBVDBZSJGPIDDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  二甲氨基氯乙烷盐酸 、 2-amino-N-(3,5-bis(trifluoromethyl)benzyl)acetamide 在 碳酸氢钠 作用下， 以 乙醇 为溶剂， 生成 N-(3,5-Bis-trifluoromethyl-benzyl)-2-(2-dimethylamino-ethylamino)-acetamide
  参考文献：
  名称：

  Discovery of 3,5-bis(trifluoromethyl)benzyl l-arylglycinamide based potent CCR2 antagonists

  摘要：

  Systematic modification of a screening lead yielded a class of potent glycinamide based CCR2 antagonists. The best compound (55, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-{[2-(1-piperidinyl)ethyl]amino}-2-(3-thienyl)acetamide) displayed good binding affinity (IC50 = 30 and 39 nM) toward human monocytes and CHO cell expressing human CCR2b, respectively. Functionally, it blocked MCP-1 (CCL2)-induced calcium mobilization (IC50 = 50 nM) and chemotaxis mediated through the CCR2 receptor (9.6 nM). It is selective against other chemokine receptors tested. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.045
• 作为产物：
  描述：

  3,5-双(三氟甲基)苄胺 在 盐酸 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 2-amino-N-(3,5-bis(trifluoromethyl)benzyl)acetamide
  参考文献：
  名称：

  Discovery of 3,5-bis(trifluoromethyl)benzyl l-arylglycinamide based potent CCR2 antagonists

  摘要：

  Systematic modification of a screening lead yielded a class of potent glycinamide based CCR2 antagonists. The best compound (55, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-{[2-(1-piperidinyl)ethyl]amino}-2-(3-thienyl)acetamide) displayed good binding affinity (IC50 = 30 and 39 nM) toward human monocytes and CHO cell expressing human CCR2b, respectively. Functionally, it blocked MCP-1 (CCL2)-induced calcium mobilization (IC50 = 50 nM) and chemotaxis mediated through the CCR2 receptor (9.6 nM). It is selective against other chemokine receptors tested. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.045

文献信息

• BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL
  申请人：Pajouhesh Hassan

  公开号：US20140187533A1

  公开（公告）日：2014-07-03

  The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) or Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions. Formula (I)

  本发明涉及用于治疗与电压门控离子通道功能相关的疾病的化合物，特别是与钠通道活性相关的疾病。更具体地说，本发明涉及化合物（例如，按照任何公式（I）-（XIII）或表1的化合物（1）-（236）的化合物），这些化合物对于治疗各种疾病和病况是有用的。公式（I）
• Heterocyclic inhibitors of the sodium channel
  申请人：DeGiacomo Mark G.

  公开号：US10208023B2

  公开（公告）日：2019-02-19

  The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic compounds (e.g., compounds according to any of Formulas (I)-(X) or Compounds (1)-(92) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotrophic lateral sclerosis, glaucoma, ischemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

  本发明涉及有助于治疗与电压门控离子通道功能有关的病症，特别是与钠通道活性有关的病症的化合物。更具体地说，本发明涉及杂环化合物（例如、根据式(I)-(X)或表 1 的化合物(1)-(92)中任一项的化合物），这些化合物可用于治疗癫痫、癌症、疼痛、偏头痛、帕金森病、情绪障碍、精神分裂症、精神病、耳鸣、肌萎缩性脊髓侧索硬化症、青光眼、缺血、痉挛性疾病、强迫症、不安腿综合征和抽动秽语综合征等病症。
• Benzimidazole inhibitors of the sodium channel
  申请人：DeGiacomo Mark G.

  公开号：US10351514B2

  公开（公告）日：2019-07-16

  The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) and in particular Formula (X), and Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions.

  本发明涉及有助于治疗与电压门控离子通道功能相关的病症，特别是与钠通道活性相关的病症的化合物。更具体地说，本发明涉及有助于治疗各种疾病和病症的化合物（例如，根据式（I）-（XIII）中任一式，特别是式(X)的化合物，以及表 1 的化合物（1）-（236））。
• Detritylation with ytterbium triflate
  作者：Rong Jian Lu、Daipei Liu、Roger W Giese

  DOI：10.1016/s0040-4039(00)00270-7

  日期：2000.4

  Ytterbium triflate catalyzes the hydrolysis of tritylamines and trityloxy compounds to the corresponding amines and alcohols under mild conditions in high yields. The reactions are conducted in tetrahydrofuran in the presence of 1 equivalent of water. (C) 2000 Elsevier Science Ltd. All rights reserved.
• HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL
  申请人：ZALICUS PHARMACEUTICALS, LTD.

  公开号：US20160016939A1

  公开（公告）日：2016-01-21

  The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic compounds (e.g., compounds according to any of Formulas (I)-(X) or Compounds (1)-(92) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotrophic lateral sclerosis, glaucoma, ischemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.